Abstract: A self-mixing interferometer configured to monitor particulate material within a monitored region of space comprising a laser cavity assembly (1A) and an optical assembly (1B) configured to bathe the monitored region with laser light of the interferometer. A laser monitoring unit (1C) is configured to acquire an interferometric signal generated by the interferometer in response to light returned to the laser cavity assembly from said wavefronts by said particulate material. A processing module (1D) is configured to determine a property of the particulate material within the monitored region according to a wavelet transformation of the interferometric signal at least a part of which comprises a waveform of changing frequency.

Abstract: A self-mixing interferometer configured to monitor particulate material within a monitored region of space comprising a laser cavity assembly (1A) and an optical assembly (1B) configured to bathe the monitored region with laser light of the interferometer possessing wavefronts having different directions at different respective locations within the monitored region. A laser monitoring unit (1C) is configured to acquire an interferometric signal generated by the interferometer in response to light returned to the laser cavity assembly from said wavefronts by said particulate material. A processing module (1D) is configured to determine a property of the particulate material within the monitored region according to changes in the frequency of a waveform within at least a part of the interferometric signal.

Abstract: A self-mixing interferometer configured to monitor particulate material within a monitored region of space comprising a laser cavity assembly (1A) and an optical assembly (1B) configured to bathe the monitored region with laser light of the interferometer. A laser monitoring unit (1C) is configured to acquire an interferometric signal generated by the interferometer in response to light returned to the laser cavity assembly from said wavefronts by said particulate material. A processing module (1D) is configured to determine a property of the particulate material within the monitored region according to a structure in data describing the interferometric signal in a frequency-space transformation thereof wherein at least a part of the interferometric signal comprises a waveform of changing frequency.

Abstract: A haircare appliance has a housing having an air inlet and an air outlet, an airflow generator for generating an airflow from the air inlet to the air outlet, and a heater for heating the airflow. The haircare appliance has an airflow temperature module for obtaining a value indicative of a temperature of the airflow at the air outlet, a distance sensor for sensing a distance to hair within a flow path from the air outlet and a temperature sensor for sensing a temperature of the hair. The haircare appliance has a moisture estimation module configured to estimate, based on received output values from the airflow temperature module, the distance sensor and the temperature sensor, a moisture content of the hair.

Abstract: An ultrasound imaging apparatus including a processing unit configured to produce an ultrasound image of the target region by applying position/orientation data representative of the position and/or orientation of an ultrasound transducer on the first side of a surface during each collection cycle to echo data representative of reflected ultrasound energy received by the ultrasound transducer during each collection cycle so as to coherently focus the echo data at a plurality of points distributed within the target region.

Abstract: An ultrasound imaging apparatus including a processing unit configured to produce an ultrasound image of the target region by applying position/orientation data representative of the position and/or orientation of an ultrasound transducer on the first side of a surface during each collection cycle to echo data representative of reflected ultrasound energy received by the ultrasound transducer during each collection cycle so as to coherently focus the echo data at a plurality of points distributed within the target region.

Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Abstract: Apparatus and a method for fast attack automatic gain control (AGC) loop for narrow band systems in which RF signals are received in discontinuous bursts, such as TETRA systems in a direct mode of operation (DMO). The loop includes a feedback loop with a predetermined non-linear response to an input signal. The method includes the steps of opening the AGC loop (250), setting a gain for the signal path of the AGC loop to a predetermined level (252), closing the AGC loop (254) and commencing a steady-state mode of operation (258).

Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Abstract: Cyclosporin A, or another compound having cyclosporin A-like activity, and cobra venom factor, or another complement inhibitor, can be used in conjunction with each other to promote allograft and concordant xenograft survival and to rescue such grafts from rejection.

Abstract: A digital signal processor (100) receives a digitally vocoded signal (102), and calculates a staggered average value (404) from the frame energy of each received frame, or the product of the frame energy and a voicing value. While the staggered average value is above a threshold voice indicator value, speech is declared present.